Drugdiscovery >> Drugs >> News
7238
Views
Thetanix, orphan drug for pediatric Crohn's disease - drugdiscovery.com
Thetanix, orphan drug for pediatric Crohn's disease - drugdiscovery.com


The FDA has granted Orphan Drug Designation to GT Biologics for its drug Thetanix (bacteroides thetaiotaomicron) for paediatric Crohn’s disease.
Read More >>


Tags: paediatric, Crohn’s disease, children, drug, orphan drug, Thetanix, GT Biologic - October 8, 2013
Related Articles
5714
Views
Orphan drug designation for Bayer’s hypertension drug riociguat Orphan drug designation for Bayer’s hypertension drug riociguat
The FDA has granted two separate orphan drug designations for riociguat, Bayer’s investigational hypertension drug, for the treatment of pulmonary arterial hypertension and chronic thromboembolic pu Read More >>

Tags: riociguat, hypertension, drug, orphan drug designation, orphan, Bayer, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

14260
Views
Orphan Drug Designation for Hemophilia B drug ALN-AT3 Orphan Drug Designation for Hemophilia B drug ALN-AT3
FDA has approved an Orphan Drug Designation to Alnylam Pharmaceuticals’ drug ALN-AT3 for the treatment of hemophilia B. ALN AT3 is subcutaneously administered RNAi therapeutic which targets antith Read More >>

Tags: orphan drug, ALN-AT3, hemophilia B, antithrombin, RNAi,Alnylam

6897
Views
ALN-AT3 gets a second Orphan Drug Designation, this time for Hemophilia A ALN-AT3 gets a second Orphan Drug Designation, this time for Hemophilia A
After last week’s approval of Orphan Drug Designation to Alnylam Pharmaceuticals’ RNAi drug ALN-AT3 for the treatment of hemophilia B, this week it is for the treatment of hemophilia A . Read More >>

Tags: orphan, drug, ALN-AT3, Alnylam, RNAi, hemophilia

8033
Views
Orphan drug designation for Delcath’s liver cancer drug Orphan drug designation for Delcath’s liver cancer drug
The FDA has granted "orphan drug" status to Delcath Systems’ melphalan hidrochloride chemotherapy for the treatment of primary liver cancer (hepatocellular carcinoma). Read More >>

Tags: melphalan, liver cancer, US, orphan drug, designation, hepatocellular carcinoma, Delcath

3086
Views
Orphan Drug designation for SGX94 for acute radiation syndrome Orphan Drug designation for SGX94 for acute radiation syndrome
Soligenix’ innate defense regulator, SGX94, is a new class of short, synthetic peptides that accelerates resolution of tissue damage following exposure to a variety of agents including radiation, c Read More >>

Tags: orphan drug, SGX94, acute radiation syndrome, Soligenix, synthetic peptides

6205
Views
Orphan Drug Designation for ReN003 retinal stem cell therapy Orphan Drug Designation for ReN003 retinal stem cell therapy
ReNeuron Group’s ReN003 retinal stem cell therapy, candidate for retinitis pigmentosa, has been granted Orphan Drug Designation in both Europe and the U.S. Read More >>

Tags: Orphan Drug Designation, ReN003, retinal stem cell therapy, retinitis pigmentosa, orphan drug, stem cell therapy

6096
Views
The future of orphan drugs The future of orphan drugs
Orphan drugs are gaining more and more popularity among drug makers. Find out why and which are the top projected 2018 sellers. Read More >>

Tags: orphan drugs, top 20, pharma companies

4788
Views
Zonegran, Eisai's epilepsy drug might soon be used in pediatric patients Zonegran, Eisai's epilepsy drug might soon be used in pediatric patients
Eisai’s Zonegran has shown to be safe and long-term effective when used as adjunctive therapy in adolescents and children aged six years and above, with partial (focal) epilepsy. Eisai is currently Read More >>

Tags: epilepsy, child, children, focal epilepsy, drug, treatment, Zonegran, zonisamide, Eisai

6341
Views
A  high blood pressure drug approved for kids too A high blood pressure drug approved for kids too
FDA has approved Silvergate Pharmaceuticals’ drug Epaned (enalapril maleate powder for oral solution) for the treatment of hypertension in patients aged one month and older. Read More >>

Tags: Epaned, hypertension, high blood pressure, children, pediatric patients

9165
Views
Orphan Drug Designation for HPV-associated anal cancer drug - ADXS-HPV Orphan Drug Designation for HPV-associated anal cancer drug - ADXS-HPV
FDA has approved an Orphan Drug Designation to Advaxis’ next generation immunotherapy drug ADXS-HPV for the treatment of human papillomavirus (HPV)-associated anal cancer. Read More >>

Tags: Advaxis, ADXS-HPV, HPV, anal cancer, human papillomavirus, immunotherapy, drug

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013